|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
JP2018536436A
(ja)
|
2015-12-04 |
2018-12-13 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
MX2019011272A
(es)
*
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Composiciones y metodos para inmunooncologia.
|
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
CN109517073A
(zh)
*
|
2018-11-30 |
2019-03-26 |
北京泽勤生物医药有限公司 |
一种靶向治疗肿瘤的融合肽及其应用
|
|
EP3896158A4
(en)
*
|
2018-12-11 |
2022-11-02 |
Kyoto University |
METHODS OF INDUCING A DELETION IN GENOMIC DNA
|
|
WO2020206055A1
(en)
*
|
2019-04-02 |
2020-10-08 |
Yale University |
Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
|
|
AU2020264484A1
(en)
|
2019-05-01 |
2021-11-04 |
Adoc Ssf, Llc |
Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy
|
|
AU2020343516A1
(en)
|
2019-09-06 |
2022-03-10 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
CN114945382A
(zh)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
Cd19和cd22嵌合抗原受体及其用途
|
|
WO2021127261A1
(en)
*
|
2019-12-17 |
2021-06-24 |
The General Hospital Corporation |
Engineered immune cells with reduced toxicity and uses thereof
|
|
CN115427451A
(zh)
*
|
2020-02-14 |
2022-12-02 |
北京永泰瑞科生物科技有限公司 |
过表达从外部导入的细胞信号调节因子的免疫细胞及其用途
|
|
US20230355671A1
(en)
*
|
2020-03-18 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases
|
|
TW202216768A
(zh)
|
2020-06-22 |
2022-05-01 |
美商恩格姆生物製藥公司 |
Ｌａｉｒ－１結合劑及其使用方法
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN113045658B
(zh)
|
2020-12-11 |
2021-12-24 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
CN113234169B
(zh)
*
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
WO2023086882A1
(en)
*
|
2021-11-11 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
CN114350665A
(zh)
*
|
2022-01-19 |
2022-04-15 |
上海优替济生生物医药有限公司 |
IFN-γ抑制剂及其用途
|
|
CN114404592A
(zh)
*
|
2022-02-09 |
2022-04-29 |
复旦大学附属中山医院 |
Tet2作为靶标在治疗缺血性血管疾病中的应用
|
|
WO2024059834A2
(en)
*
|
2022-09-15 |
2024-03-21 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Downregulating inos to increase car-t killing
|
|
WO2025189025A2
(en)
*
|
2024-03-07 |
2025-09-12 |
Biontech Us Inc. |
Methods and compositions for engineering t cells
|